Stock Track | TransMedics Group Soars 6.18% Pre-market on FDA Approval for Major Heart Transplant Trial

Stock Track

Aug 04, 2025

TransMedics Group, Inc. (TMDX) saw its stock surge 6.18% in pre-market trading on Monday following a significant announcement regarding its organ transplant technology. The company received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE), paving the way for a groundbreaking heart transplant trial.

The FDA approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial, which is set to be the largest heart preservation for transplant trial ever conducted worldwide. This two-part clinical study aims to demonstrate the benefits of prolonged heart perfusion using the company's OCS™ Heart System. The trial will compare the effectiveness of this system in donation after brain death (DBD) cases to traditional static cold storage methods, with an expected sample size exceeding 650 patients.

Investors are reacting positively to this news, as it represents a significant step forward in TransMedics' mission to transform the standard of care in cardiothoracic transplants. The large scale of the trial and its potential to improve heart transplant outcomes could lead to increased adoption of TransMedics' technology, potentially driving future growth for the company. As the medical technology firm continues to innovate in the organ transplant field, market participants appear optimistic about its prospects, reflected in the pre-market stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1135383733"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135383733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135383733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135383733","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Group Soars 6.18% Pre-market on FDA Approval for Major Heart Transplant Trial","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock surge 6.18% in pre-market trading on Monday following a significant announcement regarding its organ transplant technology. The company received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE), paving the way for a groundbreaking heart transplant trial.</p>\n\n<p>The FDA approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial, which is set to be the largest heart preservation for transplant trial ever conducted worldwide. This two-part clinical study aims to demonstrate the benefits of prolonged heart perfusion using the company's OCS™ Heart System. The trial will compare the effectiveness of this system in donation after brain death (DBD) cases to traditional static cold storage methods, with an expected sample size exceeding 650 patients.</p>\n\n<p>Investors are reacting positively to this news, as it represents a significant step forward in TransMedics' mission to transform the standard of care in cardiothoracic transplants. The large scale of the trial and its potential to improve heart transplant outcomes could lead to increased adoption of TransMedics' technology, potentially driving future growth for the company. As the medical technology firm continues to innovate in the organ transplant field, market participants appear optimistic about its prospects, reflected in the pre-market stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Group Soars 6.18% Pre-market on FDA Approval for Major Heart Transplant Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Group Soars 6.18% Pre-market on FDA Approval for Major Heart Transplant Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-04 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock surge 6.18% in pre-market trading on Monday following a significant announcement regarding its organ transplant technology. The company received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE), paving the way for a groundbreaking heart transplant trial.</p>\n\n<p>The FDA approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial, which is set to be the largest heart preservation for transplant trial ever conducted worldwide. This two-part clinical study aims to demonstrate the benefits of prolonged heart perfusion using the company's OCS™ Heart System. The trial will compare the effectiveness of this system in donation after brain death (DBD) cases to traditional static cold storage methods, with an expected sample size exceeding 650 patients.</p>\n\n<p>Investors are reacting positively to this news, as it represents a significant step forward in TransMedics' mission to transform the standard of care in cardiothoracic transplants. The large scale of the trial and its potential to improve heart transplant outcomes could lead to increased adoption of TransMedics' technology, potentially driving future growth for the company. As the medical technology firm continues to innovate in the organ transplant field, market participants appear optimistic about its prospects, reflected in the pre-market stock price surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1135383733","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135383733","pubTimestamp":1754313289,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) saw its stock surge 6.18% in pre-market trading on Monday following a significant announcement regarding its organ transplant technology. The company received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|FDA批准重大心脏移植试验TransMedics集团盘前大涨6.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock surge 6.18% in pre-market trading on Monday following a significant announcement regarding its organ transplant technology. The company received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE), paving the way for a groundbreaking heart transplant trial.\nThe FDA approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial, which is set to be the largest heart preservation for transplant trial ever conducted worldwide. This two-part clinical study aims to demonstrate the benefits of prolonged heart perfusion using the company's OCS™ Heart System. The trial will compare the effectiveness of this system in donation after brain death (DBD) cases to traditional static cold storage methods, with an expected sample size exceeding 650 patients.\nInvestors are reacting positively to this news, as it represents a significant step forward in TransMedics' mission to transform the standard of care in cardiothoracic transplants. The large scale of the trial and its potential to improve heart transplant outcomes could lead to increased adoption of TransMedics' technology, potentially driving future growth for the company. As the medical technology firm continues to innovate in the organ transplant field, market participants appear optimistic about its prospects, reflected in the pre-market stock price surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}